替加环素
脾细胞
药理学
医学
效价
体内
促炎细胞因子
免疫系统
免疫学
抗生素
微生物学
生物
抗体
生物技术
炎症
作者
Shada Y. Elhayek,Mohammad Fararjeh,Areej M. Assaf,Eman Y. Abu-rish,Yasser Bustanji
出处
期刊:Acta Pharmaceutica
[De Gruyter]
日期:2018-12-01
卷期号:68 (4): 457-469
被引量:1
标识
DOI:10.2478/acph-2018-0040
摘要
Abstract Tigecycline is a glycylcycline antibiotic approved by the FDA for the treatment of complicated infections. Despite its effectiveness, the FDA announced a warning of increasing mortality associated with its use. There is, however, no clear explanation for this side effect. Previous reports found a possible effect of tigecycline on leukocyte proliferation and proinflammatory cytokine release. We t herefore i nvestigated the effect of tigecycline on the immune components and response in Balb/c mice in vivo and in vitro. It was found that tigecycline enhanced lymphocyte proliferation and significantly increased cellular infiltration within the footpad, as based on DTH testing, but reduced the hemagglutination titer. In splenocyte cultures, tigecycline suppressed splenocyte proliferation with IC 50 3-5 mmol L -1 , significantly increased IL-2 secretion and reduced IL-17 secretion in a dose dependent mode. In conclusion, tigecycline is safe at therapeutic and sub-therapeutic doses, but it could still have an immunomodulatory effect at higher doses. Use of higher doses of tigecycline requires further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI